

## BIBLIOGRAPHY

- Abbott, T.A. 1995. Price Regulation in the Pharmaceutical Industry: Prescription or Placebo? *Journal of Health Economics*, 14: 551-565.
- Comparative Strategies in the Pharmaceutical Industry*. American Enterprise Institute, Washington D.C
- Beatty, S. 1998. Readers Digest Targets Patients by Their Ailments. *The Wall Street Journal*, April 17, 1998, pp. B1, B3.
- Bowdith, A.J. 1996. In Europe's complex market, check the price is right. *Research Plus*, April, 1996, pp. 12-13.
- Bowdith, A.J. and S. Fitall. 1995. Through the looking glass: primary research in multi-country forecasting. Proceedings, *Eph-MRA/ESOMAR Pharmaceutical Marketing Research Conference*, Geneva. ESOMAR, Amsterdam, pp. 141-163.
- Branthwaite, A. and J Bruggemann. 1996. Why we won't keep taking pills. *Research Plus*, April 1996, pp. 8-9.
- Campbell, M.F., A.B. Retik, E. D. Vaughan and P.C. Walsh. 1997. *Campbell's Urology*. Seventh Edition. W.B. Saunders Co., 3432p.
- Curtis, M. 1998. *Pricing Research Overview*. Pinnacle Research Consulting, 39p. (<http://www.gopinnacle.com/pricing>).

- Dalrymple, D.J. and L.J. Parsons. 2000. *Marketing Management, Texts and Cases*. 7<sup>th</sup> ed., John Wiley & Sons, pp. 375-416.
- De La Rosette. 1999. *Proceedings, European Urological Winter Forum, 1999*. The Netherlands., 358p.
- Diamantopoulos, A. and B. Mathews. 1995. *Making Price Decisions*. Chapman and Hall, 155p.
- Folland, S., A.C. Goodman and M. Stano. 2001. *The Economics of Health and Health Care*. Third Edition. Prentice Hall, N.J., 667p.
- Fox, A. and B. Fox. 1996. *The Healthy Prostate: A Doctors Comprehensive Program for Preventing and Treating Common Problems*. John Wiley and Sons, 256p.
- Gabor, A. and C. Grainger. 1966. Price as an indicator of quality. *Economics*, 33: 43-70.
- Grabowski, H.G. and J.M. Vernon. 1994. Prospects of Returns to R&D under Health Care Reform. In: R.B. Helms (ed.). *Comparative Strategies in the Pharmaceutical Industry*. American Enterprise Institute, Washington D.C, pp. 194-207.
- Hanna, N. and H.R. Dodge. 1995. *Pricing Policies and Procedures*. MacMillan Press Ltd., pp. 78-95.
- Hatry, H. P., C.H. Weiss and T. van Houten. 1998. *Customer surveys for Agency Managers : What Managers need to know*. Urban Inst. Pres, 120p.

- Hellerstein, J.K. 1998. The Importance of the Physician in the Generic Versus Trade-Name Prescription Decision. *RAND Journal of Economics*, 29: 108-136.
- Helms, R.B. 1996. *Comparative Strategies in the Pharmaceutical Industry*. American Enterprise Institute, Washington D.C., 285p.
- Huttin, C. 1999. Drug Price Divergence in Europe: Regulatory Aspects. *Health Affairs*, 14: 131-142.
- James Jr., L. 1999. *The Best Options for Diagnosing and Treating Prostate Cancer: Based on Research, Clinical Trials, and Scientific and Investigational Studies*. Health Education Literary Publications, 216p.
- Kolassa, E.M. 1997. *Elements of Pharmaceutical Pricing*. Haworth Press Inc., 118p.
- Kotler, P. 1997. *Market Management: Analysis, Planning, Implementation, and Control*. International Edition, Ninth Edition, Prentice Hall International Inc., N.J, p. 397.
- Lanzillotti, R.F. 1967. Pricing Objectives in Large Companies. In: D.F. Mulvihill and S. Paranka (eds.). *Price Policies and Practices*. John Wiley, N.Y., pp. 63-83.
- Levy, P.S. and S. Lemeshow. 1999. *Sampling of Populations: Methods and Applications*. Wiley Series on Survey Methodology. Wiley Interscience, Third Edition, 528p.
- Miller, P.D. 2002. *New Perspectives on Benign Prostatic Hypertrophy (BPH)*. Merit Publ. International, 124p.

- Moore, S.D. 1998. Hopes Dwindle that EU Will Dismantle Draconian Price Controls on Medicines. *The Wall Street Journal*, December 7, 1998, p A26.
- Nagle, T. T. and R. K. Holden. 1995. *The Strategy and Tactics of Pricing*. 2<sup>nd</sup> ed., Prentice Hall, N. J., Chapter 4.
- Nevin, J. R. 1974. Laboratory Experiments for Estimating Consumer Demand – A Validation Study. *Journal of Marketing Research*, August 1974, pp. 261-268.
- Proctor, T. 2000. *Essentials of Marketing Research*. 2<sup>nd</sup> ed., Prentice Hall, pp. 341-343.
- SAS. 1990. *Guide to SAS Software Package for Personal Computers*. SAS Institute Inc., N.C., 1029p.
- SDR. 2001. SDR's Premium Pricing Model: based on van Westendorp Price Sensitivity Meter.4p.(<http://www.sdrnet.com/SDRPremiumPriceWriteUp.htm>).
- Sheshinski, E and Y. Weiss. 1993. *Optimal Pricing, Inflation and the Cost of Price Adjustment*. The MIT Press, 520p.
- Schweitzer, S.O. 1996. *Pharmaceutical Economics and Policy*. Oxford University Press, N.Y.
- Vandermerwe, S. and M. Taishoff. 2000. Baxter (A). In: Dalrymple, D.J. and L.J. Parsons. (eds). *Marketing Management, Texts and Cases*. 7<sup>th</sup> ed., John Wiley & Sons, pp. 399-416.
- West, D. 1998. 'Atacand Up at Bat'. *Pharmaceutical Executive*, December 1998, p. S16.

Weiner, J. 1994. Forecasting Demand : Consumer Electronics Marketer Uses a Conjoint Approach to Configure its New Product and Set the Right Price. *Marketing Research: A Magazine of Management and Applications*, Summer 1994, pp. 6-11.

Winer, R.S. 2000. *Marketing Management*. Prentice Hall Inc., 551 p.

Zikmund, W.G. 2000. *Business Research Methods*. Sixth Edition, The Dryden Press, 660p.